title: Chronic myelogenous leukemia, version 1.2015.
abstract: Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Jerald P
authors.initials: JP
authors.lastname: Radich
authors.forename: Camille N
authors.initials: CN
authors.lastname: Abboud
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Akhtari
authors.forename: Jessica K
authors.initials: JK
authors.lastname: Altman
authors.forename: Ellin
authors.initials: E
authors.lastname: Berman
authors.forename: Peter
authors.initials: P
authors.lastname: Curtin
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: DeAngelo
authors.forename: Michael
authors.initials: M
authors.lastname: Deininger
authors.forename: Steven
authors.initials: S
authors.lastname: Devine
authors.forename: Amir T
authors.initials: AT
authors.lastname: Fathi
authors.forename: Jason
authors.initials: J
authors.lastname: Gotlib
authors.forename: Madan
authors.initials: M
authors.lastname: Jagasia
authors.forename: Patricia
authors.initials: P
authors.lastname: Kropf
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Moore
authors.forename: Arnel
authors.initials: A
authors.lastname: Pallera
authors.forename: Vishnu Vb
authors.initials: VV
authors.lastname: Reddy
authors.forename: Neil P
authors.initials: NP
authors.lastname: Shah
authors.forename: B Douglas
authors.initials: BD
authors.lastname: Smith
authors.forename: David S
authors.initials: DS
authors.lastname: Snyder
authors.forename: Meir
authors.initials: M
authors.lastname: Wetzler
authors.forename: Kristina
authors.initials: K
authors.lastname: Gregory
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017408:Guidelines as Topic; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D015465:Leukemia, Myeloid, Accelerated Phase / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases